Skip to content

Evaluation of some chemical agents and phytocompounds on the cardiovascular system

Evaluation of some chemical agents and phytocompounds on the cardiovascular system - ESCAPCS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00011035
Enrollment
200
Registered
2016-08-30
Start date
2016-10-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10-I15 J84.1

Interventions

Group 1: Patients will be interviewed once using a questionnaire. There are important factors for the development of cardiovascular diseases such as age, gender, weight and/or body mass index, smoking

Sponsors

University of Medicine and Pharmacy
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Employees at the worksite with documented exposure to coal and crystalline silica, the total time of work at the worksites with documented exposure at least 10 years, and no current exposure to other chemical or physical factors

Exclusion criteria

Exclusion criteria: Patients with a pre-bronchodilator FEV1% predicted below 40% as well as a FEV1/FVC ratio below 45%

Design outcomes

Primary

MeasureTime frame
The main aims of this study is to find the incidence of cardiovascular diseases in a group with patients exposed to coal and crystalline silica, and to correlate the risk of cardiovascular diseases with different factors and with the consumption of phytocompounds.

Secondary

MeasureTime frame
There are many phytocompound that are very important to an alternative treatment of cardiovascular diseases. Extracts of ginger and hot chilli pepper have been chosen by our team to be encapsulated inside a polyurethane carrier and the products were evaluated by physical and chemical procedures, in vivo and in vitro tests.

Countries

Romania

Contacts

Public ContactLivia-Cristina Borcan

University of Medicine and Pharmacy

borcan.cristina@umft.ro0040745329795

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026